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Abstract CD24 has been described as an adverse prognostic marker in several malignancies. This study evaluates CD24
expression in cholangiocarcinoma and correlates the findings with clinicopathologic data and patient survival. Between
1996 and 2002, 22 consecutive patients with cholangiocarcinoma were treated at our institution. Demographic data, SEER
stage, pathologic data, treatment, expression of CD24, mitogen-activated protein kinase (MAPK), phosphorylated MAPK,
and survival were analyzed. The majority of the tumors demonstrated CD24 (81.8%) and p-MAPK (87%) expression. A
negative association was noted between the expression of CD24 and p-MAPK. Median survival for patients with low
expression of CD24 was 36 months and high expression was 8 months. Median survival for patients who received
chemotherapy with low CD24 expression was 163 months, and for seven patients with high CD24 expression, it was
17 months (p=0.04). With the addition of radiation therapy, median survival for patients with low expression of CD24 was
52 months and high expression was 17 months (p=0.08). On multivariate analysis, the use of chemotherapy (p=0.0014,
hazard ratio 0.069) and the CD24 overexpression (p=0.02, hazard ratio 7.528) were predictive of survival. CD24 is
commonly expressed in cholangiocarcinoma, and overexpression is predictive of poor survival and possibly of lack of response
to chemotherapy and radiation therapy. These findings may improve selection of patients for the appropriate treatment modality




Malignancies of the biliary tract are uncommon in the
Western world. Two-thirds arise in the gallbladder and the
remainder in the biliary tree or periampullary region.
Cholangiocarcinoma or bile duct cancer is a rare but lethal
malignancy with an incidence of 1–2 cases per 100,000
patients in the United States.
1 Clinicopathologic factors
predictive of survival include curative resection, tumor stage
and grade, serum bilirubin level <10 mg/dl, low CA19-9
level, hepatitis viral infection,
2–4 lymphovascular or portal
vein invasion,
5 intrahepatic satellite lesions, inraductal
papillary compvonent, tumor angiogenesis,
6 and DNA
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7 Reports of molecular markers predictive of survival









14 p53, and p73.
15
Recently, CD24 has been described in a wide variety of
malignancies and shown to be a prognostic marker in
several solid tumors including colorectal, stomach, lung,
prostate, ovarian, and breast.
16–21 CD24 is a small, heavily
glycosylated, mucin-like, cell-surface protein expressed in
developing cells including pre-B cells, keratinocytes, and
renal tubular epithelium.
22–24 It functions as an alternative
ligand of P-selectin, an adhesion receptor expressed on
activated endothelial cells and platelets which can enhance
the metastatic potential of CD24-expressing tumor cells.
25–28
CD24 has apoptotic activity, and its cross-linking induces the
sustained activation of p38 MAPK (mitogen-activated
protein kinases)—the magnitude of which may determine
the survival or death of pre-B cells.
29 An improved
understanding of the molecular pathways involved in the
pathogenesis and progression of cholangiocarcinoma will
contribute to the development of targeted therapy.
This study correlates CD24 and MAPK expression with
patient survival in cholangiocarcinoma with the objective of




After obtaining approval of the Institutional Review Board,
a review of the tumor registry at Roswell Park Cancer
Institute identified 31 consecutive patients with histologi-
cally proven cholangiocarcinoma between 1996 and 2002.
Twenty-two patients had adequate tissue for further
histopathologic studies and constitute the basis of this
study. Medical records of these patients were reviewed for
demographic data including age; gender; surveillance,
epidemiology, and end results (SEER) stage at presentation;
treatment; and survival from the time of diagnosis.
Immunohistochemical Staining
For most of the patients, diagnosis was established by
examination of conventional hematoxylin and eosin (H&E)-
stained slides and, in the remainder diagnosis, was confirmed
with ancillary techniques including immunohistochemistry
and special histochemistry with mucin and PAS stains.
Uniform tissue fixation techniques were used for all patients.
For each patient, a representative block containing adequate
neoplastic and nonneoplastic tissue was selected. Five-
micrometer tissue sections from these blocks were placed
on charged slides and dried in a 60°C oven for 1 h. Upon
return to room temperature, the slides were deparaffinized in
three changes of xylene and rehydrated using graded
alcohols. Endogenous peroxidase was quenched with 3%
aqueous H2O2 for 15 min and washed with phosphate
buffered saline with 0.05% Tween-20 (PBS/T). CD24
primary antibody was obtained from BD Biosciences (clone
ML5) and used with the recommended incubation time and
antigen retrieval procedures. The primary antibody used for
MAPK was obtained from Cell Signaling and for phosphor-
ylated/activated MAPK from Santa Cruz. After a PBS/T
wash, 0.03% casein (in PBS/T) was used as a block for
30 min followed by the application of the primary antibody
to the slides for an hour or overnight. Another PBS/T wash
was followed by exposure to the biotinylated secondary
antibody for 30 min. A third PBS/T wash was followed by
exposure to the streptavidin–peroxidase complex for 30 min.
A PBS/T wash was followed by the application of the
chromogen DAB (DAKO, Carpinteria CA, USA) for 5 min.
T h es l i d e sw e r et h e nc o u n t e r s t a i n e dw i t hh e m a t o x y l i n ,r i n s e d
with water, dehydrated, and cleared, and a coverslip was
placed. The use of biomarkers, related controls, and
interpretation of results using the Histoscore system for
quantification of results have been described previously by
our group.
30 Histoscore was defined as the product of the
percentage of positive cells and the intensity of stain. The
grade of positive staining depended upon the intensity of
staining (0: no staining, 1: weak, 2: moderate, and 3: strong
staining) and the percentage of cells stained. The final score
was calculated as a sum of each stain intensity multiplied by
the percentage of stained cells in the area of interest. For
example: if tumor showed 50% weak, 30% moderate, and
20% strong staining, the score assigned was 50   1 ðÞ þ
30   2 ðÞ þ 20   3 ðÞ ¼ 170.
Histological Grading
The cholangiocarcinoma tissue specimens were also stained
by routine H&E stains. The specimens were graded based
on the degree of tumor differentiation using the World
Health Organization (WHO) system.
Statistical Analysis
Association between biomarker expressions in tumor tissue
was investigated using the Kendall’s tau. Biomarker
expressions were classified as high and low based on
whether their scores were above or below the median value,
and survival between low and high expressions was
compared using the log-rank test. The Kaplan–Meier
method was also used to estimate the survival curves and
median survival. The Cox’s proportional hazards survival
analysis was used in the multivariate analysis of survival
446 J Gastrointest Surg (2007) 11:445–451data to explain the effect of biomarker expressions together
with other diagnostic parameters. Patient demographics
including age, tumor grade, SEER stage, and treatment
received were considered as possible parameters for
explanatory variables in the model. All statistical tests were
two-sided with statistical significance level at 5%.
Results
Patient Characteristics
Of the 22 patients included in the study, 7 were males and
15 females. The median age was 66.5 years (range: 35–77).
SEER staging was local in 1 (4.6%), regional in 14
(63.6%), and distant in 7 (31.8%) patients. Differentiation
of the tumor was classified as grade 1 in 3 (13.6%), grade 2
in 9 (40.9%), and grade 3 in 10 (45.5%) patients according
to the WHO classification. Treatment for cholangiocarci-
noma included surgery only (n=8), surgery and chemo-
therapy (n=5), surgery and radiation (n=1), chemotherapy
only (n=2), and all three treatment modalities (n=5), and
one patient did not receive any treatment.
Immunohistochemical Staining
Normal bile duct staining was used to set the score intensity.
Most of the bile ducts were negative. Occasionally, they
demonstrated weak focal and incomplete staining as seen in
Fig. 1. The cholangiocarcinoma cells were scored as 1+
when they demonstrated weak expression of CD24, 2+ for
moderate expression, and 3+ for strong expression of
CD24. Figure 1 depicts cholangiocarcinoma positive for
CD24 expression adjacent to normal biliary epithelium. The
majority of the tumors demonstrated CD24 (81.8%) and p-
MAPK (87%) expression. Immunohistochemical staining
for these proteins was higher in malignant tissue in
comparison to normal biliary epithelium. The pattern of
stainingwasusuallyacombinationofcytoplasmicandapical,
and few specimens demonstrated the apical pattern only.
Relationship Between Biomarkers
A negative association was suggested between the expres-
sion of CD24 and phosphorylated/activated p-MAPK
(Kendall’s t=−0.32408, p=0.0501).
Survival
Median survival was 36 months for nine patients with low
expression of CD24 and 8 months for 13 patients with high
expression of CD24 as shown in Fig. 2. The median
survival for five patients who received chemotherapy with
low CD24 expression was 163 months, and for seven
patients with high CD24 expression, it was 17 months
(Fig. 3, p=0.04). Median survival for four patients treated
with radiation in the presence of low CD24 expression was
52 months, and it was 17 months for two patients with
overexpression of CD24 (Fig. 4, p=0.08). Overexpression
of CD24 continued to affect survival adversely despite the
overall improvement noted with the addition of radiation
therapy. Multivariate analysis using the Cox’s proportional
hazards survival analysis demonstrated that overexpression
of CD24 (p=0.02, hazard ratio 7.528) and use of chemo-
Figure 1 Moderately differentiated cholangiocarcinoma with over-
expression of CD24. Normal bile duct (right upper corner) demon-
strated weak apical staining, whereas neoplastic cells had strong apical
and cytoplasmic staining (20×).
Figure 2 Kaplan–Meier survival curve for patients of cholangiocar-
cinoma with low and high levels of CD24 expression (n=22). p=0.02.
Low CD24 (–––––––), high CD24 (- - - - - - - - - - - -).
J Gastrointest Surg (2007) 11:445–451 447therapy (p=0.0014, hazard ratio 0.069) were predictive of
survival (Table 1). There was no significant association
noted between survival and patient’s age, sex, SEER stage,
grade of the tumor, surgery, radiation therapy, or expression
of MAPK.
Discussion
The physiologic function of CD24 is incompletely under-
stood but it has been shown to increase tumor proliferation,
cell adhesion, motility, invasion, and apoptosis.
22–24,31
Selectins are cell adhesion molecules involved in the
rolling adhesion of leukocytes to endothelial cells and
platelets under the shear forces of circulation, and P-selectin
expressed by thrombin-activated platelets and endothelial
cells is a major ligand for CD24 on carcinoma cells.
26,27
This suggests that CD24-expressing tumor cells can
disseminate more readily due to their capacity to form
thrombi with activated platelets or to adhere to endothelial
cells. Friederichs et al.
28 have demonstrated that the
carbohydrate sialylLex abundantly expressed on human
cancers is essential for CD24-mediated rolling of tumor
cells on P-selectin, and in its absence, human adenocarci-
noma cells failed to arrest and colonize the lungs. CD24, a
metastasis-associated protein, has been recently identified
as a downstream target of Ral signaling.
32 Ral GTPases are
important mediators of transformation, tumorigenesis, and
cancer progression. Microarray by immunohistochemistry
of a human bladder cancer identified CD24 as a novel Ral-
regulated target and a prognostic biological marker.
In this study, 81.8% of patients with cholangiocarcinoma
expressed CD24. Median survival for patients with over-
expression of CD24 was significantly shorter, and the
addition of chemotherapy improved survival. A negative
association was noted between the expression of CD24 and
p-MAPK. The use of chemotherapy in patients with low
expression of CD24 was associated with a median survival
of 163 months compared to 17 months in patients with a
high CD24 expression (p=0.04). The use of radiation
therapy in patients with low expression of CD24 was also
associated with an improved survival than with over-
Figure 3 Kaplan–Meier
survival curve for patients who
received chemotherapy with low
and high levels of CD24 ex-
pression (n=12). p=0.04. Low
CD24 (–––––––), high
CD24 (– - – - – - –).
Figure 4 Kaplan–Meier
survival curve for patients who
received radiation therapy with
low and high levels of CD24
expression (n=6). p=0.08. Low
CD24 (–––––––), high CD24
(– - – - – - –).
448 J Gastrointest Surg (2007) 11:445–451expression of CD24 although the data did not attain
statistical significance possibly due to the small number of
patients in this series.
It has been reported by Taguchi et al.
29 that the cross-
linking of CD24 induces apoptosis in Burkitt’s lymphoma
enhanced by a B-cell antigen receptor (BCR)-mediated
signal. They observed that simultaneous cross-linking of
pre-BCR clearly inhibited CD24-mediated apoptosis in
pre-B cells. CD24 cross-linking also induces the sustained
activation of p38 MAPK, and whether pre-B cells survive
or die may be determined by the magnitude of MAPK
activation. Consistent with these observations, the present
study suggests an inverse association between CD24 and
p-MAPK, and eventual cellular proliferation or apoptosis
might be a consequence of the dominant effect in a
complex interplay of opposing influences.
33
Our data indicate that high expression of CD24 remains
an adverse prognosticator despite the use of additional
therapy. Chemotherapy and radiation were noted to provide
maximal survival benefit to low expressors of CD24
although the data for the use of radiation was statistically
insignificant probably due to the small number of patients
in this study. Furthermore, correlation between CD24
expression and radiation sensitivity has been noted to vary
with the cell type as in human small cell lung cancer, and
radiation doses required to induce apoptosis of CD24-
negative human ALL (acute lymphoblastic leukemia) cells
were higher than those required for CD24-positive cells,
suggesting that lack of CD24 surface antigen expression is
associated with intrinsic radiation resistance.
34,35
Hypoxia is a characteristic feature of tumor cells due to
the sustained proliferation which progressively results in an
acidic, nutrient-deprived, and hypoxic tumor microenviron-
ment. Tumor oxygenation has been identified as an
independent prognostic variable for locoregional control
and overall survival following definitive irradiation for
squamous cell carcinoma of the head, neck, and uterine
cervix.
36,37 Recent reports have indicated decreased effica-
cy of chemotherapy under hypoxic conditions in several
tumor types including pancreatic cancer and testicular
tumors.
38,39 Because treatment failure was a consequence
of hypoxia, the authors recommend novel treatment
strategies aimed at improving tumor oxygenation or
enhancing the treatment sensitivity of hypoxic tumor cells.
Aimed at identifying potential oxygen-dependent markers
in vascular endothelial cells for therapeutic intervention in
tumor angiogenesis, Scheurer et al.
40 performed a broad-
range transcriptomic analysis of selected extracellular
matrix protein gene expression levels in human umbilical
cord vein endothelial cells exposed in vitro to hypoxia for
different time periods. They noted several genes transcrip-
tionally upregulated including CD24 at late times of
exposure to hypoxia, indicating that it was a useful marker
of hypoxic activation in vascular endothelial cells. In the
present series, low expressors of CD24 demonstrated
greater survival benefit from chemotherapy and radiation
than the high expressors, suggesting that its expression may
be a marker for tumor hypoxia and response to therapy.
This finding that shows that patients with low expression of
CD24 may benefit from chemotherapy or radiation is of
importance because it has been previously reported that
adjuvant or palliative radiation had no effect on survival in
patients with cholangiocarcinoma.
41 However, the small
number of patients in the present series limits interpretation
of data suggesting that CD24 overexpression may be
predictive of lack of response to radiation or chemotherapy.











<68 11 17 (8–36) 0.60
>68 11 11 (5–52)
Gender
Male 7 12 (8–163) 0.52
Female 15 17 (6–52)
Grade
1, 2 12 15 (6–52) 0.99
31 0 1 1 ( 8 –*)
SEER stage
1, 2 15 11 (6–52) 0.48
3 7 28 (6–163)
Chemotherapy
No 10 6 (4–13) 0.0005 0.0014
Yes 12 52 (17–163)
Radiation
No 16 8 (6–28) 0.12
Yes 6 44 (17–*)
Surgery
No 3 8 (0–28) 0.17
Yes 19 17 (7–52)
MAPK
Low 10 17 (8–36) 0.68
High 11 28 (5–163)
P-MAPK
Low 10 13 (8–52) 0.34
High 11 36 (4–163)
CD24
<120 9 36 (13–163) 0.10 0.02
>120 13 8 (6–28)
*The estimate was not provided because the upper limit of the survival
curve had not reached a 50% failure rate.
CD denotes cluster of differentiation.
p-MAPK denotes phosphorylated form of mitogen-activated protein
kinase.
J Gastrointest Surg (2007) 11:445–451 449CD24 has been shown to be a prognostic marker for
shortened survival and disease progression in several
malignancies including colorectal, stomach, lung, prostate,
ovarian, and breast cancers.
16–21 Weichert et al. report that
in colorectal cancer, only the subset of patients with
exceptionally strong cytoplasmic CD24 staining comprising
10% of their study group demonstrated a markedly
shortened mean survival of 31.5 months compared to
67.5 months for the remaining patients.
16 They also
reported that cytoplasmic CD24 staining pattern is prog-
nostically more significant than the membranous pattern—
the biological significance of which was unclear. Su et al.
noted a 51% expression of CD24 by immunohistochemistry
in intrahepatic cholangiocarcinoma as compared to the
81.8% in the present series. They reported CD24 expression
and tumor stage as independently predictive of survival on
multivariate analysis and suggested membrane-bound
CD24 protein as a potential target for immunotherapy.
8
In conclusion, overexpression of the molecular marker
CD24 in cholangiocarcinoma is predictive of poor survival.
CD24 overexpressors demonstrated a lack of response to
chemotherapy and possibly radiation therapy although these
observations were limited by the small sample size.
Additional properties of tumor proliferation, invasion,
metastasis, and apoptosis make CD24 a potent target for
specifically directed molecular therapy and its overexpres-
sion a potential criterion in the selection of patients for the
appropriate conventional treatment modality.
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